| Literature DB >> 24367491 |
Ponnurengam Malliappan Sivakumar1, Nozomi Moritsugu1, Sei Obuse1, Takashi Isoshima1, Hideo Tashiro2, Yoshihiro Ito3.
Abstract
We developed an automated diagnostic system for the detection of virus-specific immunoglobulin Gs (IgGs) that was based on a microarray platform. We compared efficacies of our automated system with conventional enzyme immunoassays (EIAs). Viruses were immobilized to microarrays using a radical cross-linking reaction that was induced by photo-irradiation. A new photoreactive polymer containing perfluorophenyl azide (PFPA) and poly(ethylene glycol) methacrylate was prepared and coated on plates. Inactivated measles, rubella, mumps, Varicella-Zoster and recombinant Epstein-Barr viruse antigen were added to coated plates, and irradiated with ultraviolet light to facilitate immobilization. Virus-specific IgGs in healthy human sera were assayed using these prepared microarrays and the results obtained compared with those from conventional EIAs. We observed high correlation (0.79-0.96) in the results between the automated microarray technique and EIAs. The microarray-based assay was more rapid, involved less reagents and sample, and was easier to conduct compared with conventional EIA techniques. The automated microarray system was further improved by introducing reagent storage reservoirs inside the chamber, thereby conserving the use of expensive reagents and antibodies. We considered the microarray format to be suitable for rapid and multiple serological diagnoses of viral diseases that could be developed further for clinical applications.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24367491 PMCID: PMC3867344 DOI: 10.1371/journal.pone.0081726
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Synthesis scheme for photo-reactive PEG.
19F NMR shifts and high resolution mass analysis of synthesized compounds.
| Compound | 19F NMR shifts | High Resolution Mass data (M+Na)+ | ||
| Fa | Fb | Theoretical | Experimental | |
| 4-amino-2,3,5,6-tetrafluorobenzoic acid | −162.5 | −139.1 | ||
| 4-azido-2,3,5,6-tetrafluorobenzoic acid | −151.0 | −137.2 | 257.9897 | 257.9896 |
| 2,5-dioxopyrrolidin-1-yl 4-azido-2,3,5,6-tetrafluorobenzoate | −151.8 | −134.2 | 355.0061 | 355.0063 |
| N-(2-acrolylaminoethyl)-4-azido-2,3,5,6-tetrafluorobenzamide | −150.8 | −141.3 | 354.0585 | 354.0589 |
The position of two sets of fluorine atoms (Fa and Fb) in 4-amino-2,3,5,6-tetrafluorobenzoic acid is shown in Figure S1.
Figure 2Preparation of the photo-immobilized virus microarray.
Figure 3(i) The automated microarray system. (ii) Structure of the automated microarray system. A, protein chip; B, chip and reagent holder; C, digital video camera; D, control and analysis PC; E, belt-drive system; F, pumps; G, needle holder; r1, serum; r2, enzyme-labeled antibody; r3, chemiluminescence reagent; r4, TBS; r5, TBST; r6, liquid waste. (iii) Movements of the automated microarray system. Procedure; Step 1 (preparation for reaction): At Position I, set a protein chip (A) to the holder (B). Inject serum (r1) onto the chip and stir. Inject enzyme-labeled antibody (r2) and chemilumigenic reagent (r3) to the reagent holder (B). Step 2 (wash): The holder moves to Position III, and serum is wasted out. TBS (r4) is injected and wasted, and then TBST (r5) is injected and wasted. Step 3 (reaction): The holder moves to Position II, and r2 is sucked up to the needle. Moves to Position III, r2 is injected on the chip, and stir. Step 4 (wash): The holder moves to Position III, and b is wasted out. TBS (r4) is injected and wasted, and then TBST (r5) is injected and wasted. Step 5 (preparation for imaging): The holder moves to Position II, and r3 is sucked up to the needle. Moves to Position III, and r3 is injected onto the chip. Step 6 (imaging): The holder moves to Position IV and images are taken by the digital video camera (C). Step 7 (completion): The holder moves back to Position I, and the chip is removed.
Figure 4UV spectra of azidoaniline, perfluoro-4-azidobenzoic acid and photo-reactive PEG.
Figure 5Refractive index of the photo-reactive PEG determined by spectroscopic ellipsometry.
Figure 6SEM photomicrographs of immobilized viruses.
Figure 7Images of photo-immobilized microarrays following completion of the reaction.
(i) Viruses assayed by microarrays (ii) Acquired image following a 5 s exposure. (iii) Acquired image following a 60 s exposure.
Flow chart of our automated microarray assay.
| Process | Conditions | Times | Time | |
| 1 | Primary reaction (immobilized virus and serum IgG) | With shaking | 1 | 8 min |
| 2 | TBST washing | With shaking (600 µL each time) | 2 | 3.5 min |
| 3 | TBS washing | With shaking (800 µL each time) | 13 | |
| 4 | Second reaction (adsorbed IgG and HRP-conjugated anti-IgG antibody) | With shaking | 1 | 4 min |
| 5 | TBST washing | With shaking (600 µL each time) | 2 | 3.5 min |
| 6 | TBS washing | With shaking (800 µL each time) | 13 | |
| 7 | Addition of chemical luminescence agents | 1 | 3 s | |
| 8 | CCD image | 5 s and 60 s |
Total = approx. 20 min.
Statistical equations and correlation coefficients for the comparison between the microarray and EIA results from human serum samples (n = 40).
| Virus | Equation: | Correlation coefficient | |
| Chemiluminesence (microarray) = a* absorbance (EIA)+b | |||
| a | b | ||
| Epstain-Barr virus | 184 | 747 | 0.79 |
| Varicella-Zoster virus | 320 | −1313 | 0.96 |
| Mumps | 1509 | −101.26 | 0.79 |
| Rubella | 106 | −590 | 0.84 |
| Measles | 562 | 7039 | 0.85 |
Results from various virus microarrays compared with EIA results, along with observed diagnostic specificity (DSP) and diagnostic sensitivity (DSN).
| Antibody | No of samples (obtained both Microarray and EIA) | Micorarray results against antibody (compared to EIA) | DSP | DSN | ||
| IgG positive | IgG negative | E | ||||
| Epstain-Barr Virus-G positive | 40 | 39 | 1 | 0 | ― | 100% |
| Epstain-Barr Virus-G negative | 0 | 0 | 0 | |||
| Varicella-Zoster virus G positive | 36 | 34 | 0 | 1 | ― | 100% |
| Varicella-Zoster virus G negative | 0 | 0 | 1 | |||
| Mumps G positive | 35 | 21 | 0 | 11 | ― | 100% |
| Mumps G negative | 0 | 0 | 3 | |||
| Rubella G positive | 40 | 34 | 0 | 0 | 100% | 100% |
| Rubella G negative | 0 | 5 | 1 | |||
| Measles G positive | 40 | 37 | 0 | 0 | ― | 95% |
| Measles G negative | 2 | 0 | 1 | |||
DSP, diagnostic specificity; DSN, diagnostic sensitivity.